Market Cap: $9.42B
CI
Corcept Therapeutics Incorporated
CORT
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $9.42B
Corcept Therapeutics Incorporated ( CORT ) has been making significant strides in the pharmaceutical landscape, particularly in the treatment of serious metabolic and oncological disorders. The compan…
Corcept Therapeutics (Ticker: CORT) has recently made headlines by resubmitting its New Drug Application (NDA) to the FDA for relacorilant, a treatment aimed at Cushing’s syndrome. This strategic move…
Corcept Therapeutics (Ticker: CORT) has made a significant move in the pharmaceutical landscape by resubmitting its New Drug Application (NDA) to the FDA for relacorilant, targeting Cushing’s syndrome…
Corcept Therapeutics (Ticker: CORT) continues to advance its position in the field of metabolic disease treatment by presenting promising data from its recent clinical trials. At the American Diabetes…
Corcept Therapeutics (Ticker: CORT) advances its position in the oncology space following promising trial results for its ovarian cancer drug, Lifyorli. The company's recent announcement highlights a…
Corcept Therapeutics (Ticker: CORT) announces significant advancements in its ovarian cancer treatment, Lifyorli, bolstered by data from a successful Phase 3 trial. The ROSELLA trial's results show ro…
Corcept Therapeutics has released significant long-term survival data from its Phase 2 DAZALS trial for the investigational drug dazucorilant in patients with Amyotrophic Lateral Sclerosis (ALS). The…
Corcept Therapeutics Faces Legal Challenges Over Misleading Drug Trial Information Corcept Therapeutics Incorporated is currently embroiled in multiple class action lawsuits accusing the company of se…
Emerging Legal Challenges for Corcept Therapeutics Amid Clinical Trial Allegations Corcept Therapeutics finds itself embroiled in a series of class action lawsuits that could have significant implicat…
Corcept Therapeutics Faces Class Action Lawsuit Over Drug Approval Misrepresentations Corcept Therapeutics is grappling with multiple class action lawsuits initiated by investors who claim significant…
Corcept Therapeutics Faces Class Action Lawsuits Over Regulatory Misstatements Corcept Therapeutics Incorporated is currently embroiled in legal challenges stemming from allegations of misleading stat…
Corcept Therapeutics Faces Class Action Suit Over Misleading FDA Communications Corcept Therapeutics Incorporated, a biopharmaceutical company focused on developing treatments for metabolic and psychi…
Corcept Therapeutics Faces Class Action Lawsuits Over Regulatory Misrepresentation Corcept Therapeutics Incorporated is currently entangled in multiple class action lawsuits stemming from allegations…
Corcept Therapeutics Faces Class Action Over Misleading Statements on relacorilant Approval Corcept Therapeutics Incorporated is embroiled in legal troubles following the announcement of multiple clas…
Class Action Lawsuit Highlights Corporate Accountability in Biopharmaceutical Sector In a significant development for Corcept Therapeutics Incorporated, two law firms have announced class action lawsu…
Class Action Lawsuit Looms for Corcept Therapeutics Amid Clinical Trial Controversy Corcept Therapeutics Incorporated, a company focused on developing innovative treatments for cancer and related diso…
Corcept Therapeutics Faces Legal Challenges Over Misleading Statements on Relacorilant Corcept Therapeutics Incorporated finds itself embroiled in a securities class action lawsuit due to allegations…
### Legal Troubles for Corcept Therapeutics: Class Action Lawsuits Emerge Corcept Therapeutics Inc. finds itself in substantial legal turmoil following the announcement of multiple class action lawsui…
Corcept Therapeutics Faces Class Action Lawsuits Over Misleading Statements on Relacorilant Corcept Therapeutics Incorporated finds itself at the center of two class action lawsuits, both filed on Mar…
Corcept Therapeutics Faces Legal Challenges Over Alleged Misleading Claims Corcept Therapeutics Incorporated is currently embroiled in serious legal difficulties with two separate class action lawsuit…
Corcept Therapeutics Faces Class Action Lawsuits Over Misleading Claims Regarding Relacorilant Corcept Therapeutics Incorporated (NASDAQ: CORT) is currently encountering significant legal challenges a…
Class Action Lawsuit Targets Corcept Therapeutics Over Regulatory Misrepresentation A class action lawsuit has surfaced against Corcept Therapeutics Inc., spotlighting troubling allegations about the…
Corcept Therapeutics Faces Class Action Lawsuit Over Relacorilant Claims Corcept Therapeutics Inc. stands at the center of a class action lawsuit filed by Robbins LLP, which represents investors who p…
Corporate Transparency Under Scrutiny at Corcept Therapeutics Corcept Therapeutics Inc. is currently embroiled in a class action lawsuit stemming from allegations of misleading investors regarding the…
Corcept Therapeutics Faces Class Action Lawsuit Over NDA Process for Relacorilant Corcept Therapeutics Incorporated is currently embroiled in legal challenges as Robbins Geller Rudman & Dowd LLP initi…